Clinical Trials Sponsored by Ironshore Pharmaceuticals and Development, Inc

Total 886 results

Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD (CEES)

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Attention-Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

Attention Deficit Hyperactivity Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit Hyperactivity Disorder

Canada
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Amyloidosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Pneumonia | Ventilators, Mechanical
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

NSCLC

United States
Teva Pharmaceuticals USA
Teva Pharmaceuticals Development, Inc.

Completed

Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Chronic Urticaria

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

China, Belgium, Thailand, United States, Spain, Canada, Colombia, Italy, Morocco, Brazil, Turkey, Chile, Malaysia, Israel, Portugal, Singapore, Russian Federation, Philippines, Tunisia, Austria, Czechia, Germany, Hungary, India, Poland, R... and more
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy

United States
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Neurobehavioral Disinhibition

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

Binge-Eating Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Active, not recruiting

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Attention-deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Agitation in Participants With Dementia of the Alzheimer's Type

United States, Canada
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

Epilepsy

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

Intermittent Explosive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

United States, Spain, Hungary, South Africa, Croatia, France, Poland, India, Canada, Sweden, Malaysia
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Atopic Dermatitis

Poland, United States, Australia
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

Schizophrenia | Schizoaffective Disorder | First Episode Psychosis

United Kingdom
Otsuka Pharmaceutical Development & Commercialization...

Completed

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (ASPIRE)

Schizophrenia

United States, India, South Africa, Estonia, Russian Federation, Mexico, Korea, Republic of, Malaysia, Bulgaria, Hungary, Croatia, Serbia, Poland, Romania, Puerto Rico, Slovakia, Chile, Taiwan, Thailand, Australia, Spain, Argentina, Finlan... and more
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

Multidrug-resistant Tuberculosis

South Africa, Estonia, Philippines, Peru, Lithuania, Latvia, Moldova, Republic of

Clinical Trials Sponsored by Ironshore Pharmaceuticals and Development, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations